|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 100 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Pollen Allergy Overview
- Therapeutics Development
- An Overview of Pipeline Products for Pollen Allergy
- Pollen Allergy Therapeutics under Development by Companies
- Pollen Allergy Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Pollen Allergy Therapeutics – Products under Development by Companies
- Pollen Allergy Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Pollen Allergy Therapeutics Development
- Merck & Co., Inc.
- ALK-Abello A/S
- Taiho Pharmaceutical Co., Ltd.
- Allergy Therapeutics plc
- Stallergenes S.A.
- Allergopharma Joachim Ganzer KG
- Circassia Holdings Ltd.
- ImVisioN Therapeutics AG
- Laboratorios LETI S.L.
- ANERGIS SA
- REGiMMUNE Corporation
- Immunomic Therapeutics, Inc.
- Biomay AG
- Pollen Allergy – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Pollinex Quattro Japanese Cedar - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Sublingual MPL - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pollinex Quattro Tree - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pollinex Quattro Grass - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pollinex Quattro Grass - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Allergen Extract Of Phleum Pratense - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Birch Pollen Allergoid - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MK-7243 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ToleroMune Grass Allergy T-cell Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grazax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grazax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Phleum Pratense - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AL0206st - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- gpASIT + TM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Oralair - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ALK Birch Pollen Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Epicutaneous Allergen Patch - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IVN-Birch - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RGI-1001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Pollen Allergen B-Cell Peptide Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Birch Pollen Allergen Peptide Carrier Fusion Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Birch Allergen RNA Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Allergen RNA Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Japanese Cedar RNA Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BM32 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Japanese Cedar Hypoallergenic Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Birch Allergen Specific IgG - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Allergen Specific IgG - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TAC-201 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ToleroMune Birch Allergy T Cell Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bet V 1AF1-Alum + Bet V 1AF2-Alum - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Hypoallergenic Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MULTI-LAMP Vax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AllerG - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AllerJ - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pollen Allergy Therapeutics – Drug Profile Updates
- Pollen Allergy Therapeutics - Dormant Products
- Pollen Allergy – Product Development Milestones
- Featured News & Press Releases
- Aug 03, 2012: FDA Lifts Clinical Hold On Allergy Therapeutics's Grass Pollen Allergy Vaccine
- Jun 14, 2012: Biomay Reports Promising Results From Phase IIa Trial Of Allergy Vaccine
- Mar 21, 2012: Paladin Labs Receives Canadian Approval For Oralair
- Mar 02, 2012: ALK Publishes Landmark Results Showing Long-Term Disease Modifying Effect Of GRAZAX In American Journal Of Allergy And Clinical Immunology
- Oct 25, 2011: Biomay Initiates Phase II Trial Of Grass Pollen Allergy Vaccine BM32
- May 24, 2011: Paladin Labs Files New Drug Submission For Oralair
- May 18, 2011: Stallergenes Obtains Marketing Authorization For Oralair In Australia
- Apr 18, 2011: ALK To Receive GRAZAX Reimbursement In Denmark
- Aug 31, 2010: Anergis's Ultra-Fast Treatment Against Birch Pollen Allergy Demonstrates Long Term Immunoregulatory Effect
- Jul 17, 2009: Anergis Reports Encouraging Seasonal Clinical Results With Birch Pollen Allergy Drug Candidate AllerT
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Pollen Allergy, H2 2012
- Products under Development for Pollen Allergy – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2012
- Merck & Co., Inc., H2 2012
- ALK-Abello A/S, H2 2012
- Taiho Pharmaceutical Co., Ltd., H2 2012
- Allergy Therapeutics plc, H2 2012
- Stallergenes S.A., H2 2012
- Allergopharma Joachim Ganzer KG, H2 2012
- Circassia Holdings Ltd., H2 2012
- ImVisioN Therapeutics AG, H2 2012
- Laboratorios LETI S.L., H2 2012
- ANERGIS SA, H2 2012
- REGiMMUNE Corporation, H2 2012
- Immunomic Therapeutics, Inc., H2 2012
- Biomay AG, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Pollen Allergy Therapeutics – Drug Profile Updates
- Pollen Allergy Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Pollen Allergy, H2 2012
- Products under Development for Pollen Allergy – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractPollen Allergy – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the Pollen Allergy therapeutic pipeline. This report provides information on the therapeutic development for Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pollen Allergy. 'Pollen Allergy - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Pollen Allergy.
- A review of the Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pollen Allergy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Pollen Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pollen Allergy pipeline depth and focus of Pollen Allergy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
